Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Evorpacept (ALX148)
Evorpacept · 1 trial · 1 indication
To determine the recommended dose (RD) of evorpacept (ALX148) in combination with cetuximab and pembrolizumab
To determine the objective response rate (ORR), defined as partial response or complete response, with evorpacept (ALX148), cetuximab, and pembrolizumab using RECIST v1.1 in patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC) who have progressed on at least two lines of standard therapy
| Arm | Type | Description |
|---|---|---|
| Evorpacept (ALX148) + cetuximab + pembrolizumab | EXPERIMENTAL | Evorpacept (ALX148) + cetuximab + pembrolizumab. Evorpacept (ALX148) 15 mg/kg IV weekly, cetuximab 400 mg/m2 once then 250 mg/m2 weekly, and pembrolizumab 200 mg every 3 weeks |
| Name | Type | Description |
|---|---|---|
| Evorpacept (ALX148) | DRUG | IV QW |
| Cetuximab | DRUG | IV QW |
| Pembrolizumab | DRUG | IV Q3W |
Inclusion Criteria: To be eligible to participate in this study, an individual must meet all of the following criteria: * Have a diagnosis of metastatic colorectal cancer previously treated with at least two lines of therapy for unresectable/metastatic disease * Have microsatellite stable disease ...
Evorpacept is being studied for the treatment of Microsatellite Stable Metastatic Colorectal Cancer. It is an investigational small molecule in Phase 2 clinical development. The drug is being evaluated in combination with cetuximab and pembrolizumab for patients with refractory microsatellite stable metastatic colorectal cancer.
Evorpacept targets CD47, a protein that cancer cells use to evade the immune system. By blocking CD47, Evorpacept may enhance the ability of the immune system to attack cancer cells. This mechanism is being studied in the context of microsatellite stable metastatic colorectal cancer.
Evorpacept is being developed by Merck & Company, Inc., which is listed on the stock exchange under the ticker symbol MRK. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with microsatellite stable metastatic colorectal cancer.
Evorpacept is currently in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA. The ongoing Phase 2 trial is active but not recruiting participants, and it is studying the drug in combination with other therapies for refractory microsatellite stable metastatic colorectal cancer.
Evorpacept is being studied in a Phase 2 clinical trial with the identifier NCT05167409. This trial is titled 'A Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer.' The trial is active but not recruiting, with an enrollment of 48 participants in the United States.
Yes, Evorpacept is also known as ALX148. The drug is referred to by both names in clinical research. The ongoing Phase 2 trial NCT05167409 uses the name Evorpacept (ALX148) to describe the investigational therapy being studied for microsatellite stable metastatic colorectal cancer.